Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
Advanced Endovascular Aortic Research Program, Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
J Vasc Surg. 2020 Aug;72(2):457-469.e2. doi: 10.1016/j.jvs.2019.10.062. Epub 2020 Jan 25.
The aim of this study was to evaluate outcomes of fenestrated-branched endovascular aortic repair (F-BEVAR) of pararenal abdominal aortic aneurysms or thoracoabdominal aortic aneurysms (TAAAs) in patients with a solitary functional kidney (SFK).
We analyzed the outcomes of 287 consecutive patients (206 male; mean age, 74 ± 8 years old) enrolled in a prospective nonrandomized study to investigate use of F-BEVAR for treatment of patients with pararenal abdominal aortic aneurysms or TAAAs between 2013 and 2018. Outcomes were analyzed in patients with solitary kidney (functional or congenital) and compared with control patients who had two functioning kidneys. Acute kidney injury (AKI) was defined using Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease criteria, and renal function deterioration (RFD) was defined by a decline in estimated glomerular filtration the estimated glomerular filtration rate of more than 30% from baseline. End points included 30-day mortality and major adverse events, AKI, freedom from RFD, and patient survival.
There where 30 patients (10%) with a SFK and 257 patients with two functioning kidneys. Patients with a SFK were younger and had significantly (P < .05) higher baseline creatinine (+0.3 mg/dL), lower estimated glomerular filtration rate (-16 mL/minute/1.73 m) and more often had stage III to V chronic kidney disease (73% vs 43%). There were no differences in cardiovascular risk factors and aneurysm extent. Technical success was achieved in 98.9% of patients with SFK and in 99.8% of controls (P = .10). At 30 days, there was no significant differences in mortality (0% vs 1%) and major adverse events (40% vs 24%; P = .08), including rates of AKI (20% vs 12%) and new-onset dialysis (3% vs 1%) between patients with a SFK and the control group, respectively. Mean follow-up was 18 ± 15 months. At 2 years, there was no difference (P = .36) in patient survival (92 ± 5% vs 84 ± 3%) and freedom from RFD (100 ± 0% vs 84 ± 3%) for patients with SFK and controls, respectively. Presence of a SFK was not a predictor for AKI or RFD. By multivariable analysis, estimated blood loss of more than 1 L (odds ratio [OR], 2.9; P = .04) and total fluoroscopy time (OR, 1.8; P = .05) were predictors for AKI, and postoperative AKI (OR, 4.9; P < .001), renal branch occlusion/stenosis (OR, 3.1; P = .001), and Crawford extent II TAAA (OR, 2.4; P = .007) were predictors for RFD.
Despite the worse baseline renal function, F-BEVAR is safe and effective with nearly identical outcomes in patients with a SFK as compared with patients with two functioning kidneys. Development of postoperative AKI is the most important predictor for RFD.
本研究旨在评估在孤立功能肾(SFK)患者中,使用分支型腔内修复术(F-BEVAR)治疗肾周腹主动脉瘤或胸腹主动脉瘤(TAAA)的结果。
我们分析了 2013 年至 2018 年间,287 例连续患者(206 例男性;平均年龄 74±8 岁)参与的前瞻性非随机研究中使用 F-BEVAR 治疗肾周腹主动脉瘤或 TAAA 的结果。在孤立肾(功能性或先天性)患者中分析了结果,并与具有两个功能肾的对照组患者进行了比较。急性肾损伤(AKI)使用风险、损伤、衰竭、丧失肾功能和终末期肾病标准定义,肾功能恶化(RFD)定义为肾小球滤过率估计值从基线下降超过 30%。终点包括 30 天死亡率和主要不良事件、AKI、RFD 无复发和患者生存率。
有 30 例(10%)SFK 患者和 257 例两个功能肾患者。SFK 患者更年轻,基线肌酐显著升高(+0.3mg/dL),肾小球滤过率估计值较低(-16ml/min/1.73m),更常患有 III 至 V 期慢性肾脏病(73% vs 43%)。SFK 患者和对照组患者的技术成功率分别为 98.9%和 99.8%(P=0.10)。30 天时,SFK 患者的死亡率(0% vs 1%)和主要不良事件(40% vs 24%)无显著差异(P=0.08),包括 AKI 发生率(20% vs 12%)和新发透析率(3% vs 1%),SFK 患者与对照组患者分别为 20%和 12%。平均随访时间为 18±15 个月。2 年后,SFK 患者和对照组患者的患者生存率(92±5% vs 84±3%)和 RFD 无复发率(100±0% vs 84±3%)无差异(P=0.36)。SFK 的存在不是 AKI 或 RFD 的预测因素。多变量分析显示,失血量大于 1L(比值比[OR],2.9;P=0.04)和总透视时间(OR,1.8;P=0.05)是 AKI 的预测因素,术后 AKI(OR,4.9;P<0.001)、肾分支闭塞/狭窄(OR,3.1;P=0.001)和 Crawford 程度 II TAAA(OR,2.4;P=0.007)是 RFD 的预测因素。
尽管 SFK 患者的基线肾功能较差,但 F-BEVAR 是安全有效的,SFK 患者的结果与两个功能肾患者几乎相同。术后 AKI 的发生是 RFD 的最重要预测因素。